The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer space across the eight major markets of the USA, France, Germany, Italy, Spain, the UK, Japan, and China is set to hit $9.89 billion in 2025, predicts a report from research and consulting firm GlobalData.
But the report states that growing uptake of biosimilars across these markets will hit the revenue earned by the Swiss pharma giant Roche (ROG: SIX), the dominant drugmaker in this space.
"Considering the generally high uptake of biosimilars in European markets, the launch of trastuzumab biosimilars is expected to have a significant effect on the market"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze